Alamar Q1 revenue doubled to $26.0M; net loss $21.3M on convertible note remeasurement

Alamar Biosciences, Inc.

2026-Q1 EPS reported -$1.74 revenue$26,035,000

Total revenue $26.0M, +99% YoY; consumable revenue surged 178% to $14.0M.
Gross margin improved to 56% from 49% on manufacturing efficiencies and product mix.
Net loss $21.3M, including $8.6M non-cash loss on convertible notes; operating loss $12.3M.
Cash $69.5M at March 31; after quarter-end IPO raised $197.8M net proceeds.
Launched NULISAseq Neuro 220 Panel and NULISAqpcr AD 5-plex in Q1.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Alamar Biosciences, Inc. reported the quarter ended March 31, 2026 results: revenue $26.0 million, net income $21.3 million.

Period: the quarter ended March 31, 2026
Revenue: $26.0 million
Net income: $21.3 million
Result: reported results

Exact text from the filing

Proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended March 31, 2026. Recent Highlights • Generated $26.0 million of total revenue for the first quarter of 2026, an increase of 99% as compared to the corresponding period of 2025. • Launched two new products, NULISAseqTM Neuro 220 Panel and

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Alamar Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-213379

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.